Eyeworld Daily News

2017 ASCRS Los Angeles Daily Tuesday

EyeWorld Today is the official daily of the ASCRS Symposium & Congress. Each issue provides comprehensive coverage editorial coverage of meeting presentations, events, and breaking news

Issue link: https://daily.eyeworld.org/i/821901

Contents of this Issue


Page 1 of 63

Marks designated ® and ™ are owned by Shire or an affi liated company. ©2016 Shire US Inc. Lexington, MA 02421 S24434 11/16 Please see the adjacent page for Brief Summary of Safety Information and visit Xiidra-ECP.com for Full Prescribing Information. Indication Xiidra ® (lifi tegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED). Important Safety Information In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis. To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface. Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration. Safety and effi cacy in pediatric patients below the age of 17 years have not been established. Reference: 1. FDA approves new medication for dry eye disease. FDA News Release. July 2016. http://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm510720.htm. Accessed July 12, 2016. Xiidra is a lymphocyte function-associated antigen-1 (LFA-1) antagonist, the fi rst medication in a new class of drugs. 1 Check it out at Xiidra-ECP.com The fi rst prescription eye drop FDA-approved to treat both the signs and symptoms of Dry Eye Disease BIIG DEAL Kind of a

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld Daily News - 2017 ASCRS Los Angeles Daily Tuesday